Novel laboratory model may shine light on development of pediatric high-grade glioma

Oct 27 2017

Pediatric high-grade glioma is the primary cause of cancer death in children. Genesis of these tumors is believed to be driven by mutations in proteins that disrupt fundamental mechanisms governing the development of the human brain. However, our understanding of these tumors remains incomplete due to the lack of faithful experimental models. Now, researchers of the German Center for Neurodegenerative Diseases (DZNE) together with colleagues from Canada and the UK present in the journal "Cancer Cell" a novel laboratory model that replicates key hallmarks of this disease. Results might pave the way for a better understanding of processes, relevant for both cancer and neurodegeneration.

Pediatric high-grade glioma (pHGG) is a devastating illness and the most deadly cancer affecting children. Mutations in "histone 3.3", a DNA-binding protein that acts upon gene expression for regulation of brain function and aging, are considered to play a pivotal role for the development of these tumors. "Current treatment involves surgery, radiation and chemotherapy, albeit with limited success. Most patients die within one to two years from diagnosis," says Prof. Paolo Salomoni, who leads a research group at the DZNE's Bonn site. For the current study, his team cooperated with the lab of Prof. Nada Jabado at McGill University in Montreal and with researchers from other institutions.

"Up to now, there was no truly representative in vivo model to study the underlying mechanisms of this disease," says Salomoni. "That is why we decided to develop a mouse model that recapitulates hallmark pathological features of pHGG. Our findings support the concept that mutations in histone 3.3 alter gene regulation already during embryonic development. This means that the cancer likely starts in utero."

For the study the researchers altered the blueprint of histone 3.3 in mice by genetic engineering. "This model will enable insights into the development of pHGG and provide an opportunity to explore novel therapeutic approaches", Salomoni says. The biologist sees further potential for applications: "Laboratory experiments from DZNE and others suggest that alterations in histone 3.3 are implicated not just in brain tumors but also in depression and age-related brain diseases. Our model might, therefore, help to study DNA associated mechanisms involved in a wide spectrum of diseases."